Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer
Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Aug 15, 2023
Trial Information
Current as of April 28, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to treat locally advanced cervical cancer using a type of radiation therapy called moderately hypofractionated adaptive radiotherapy. This method involves giving radiation in fewer sessions (or fractions) than the standard treatment, while also using weekly chemotherapy. The goal is to see how effective this treatment is and what side effects might occur compared to the usual care.
To participate in this trial, women aged 18 to 70 who have specific stages of cervical cancer (like stage IB or IIA) may be eligible, provided they meet certain health criteria. Participants can expect to receive advanced radiation therapy along with chemotherapy, and they will be closely monitored for their response to treatment and any side effects. It’s important to note that patients who have had prior treatments for their cancer or have more advanced stages may not qualify for this study. If you think you might be eligible or are interested in learning more, please discuss it with your healthcare provider.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age 18 years to 70 years
- • FIGO Stage IB1, IB2, IB3, IIA or IIB cervical cancers
- • FIGO stage IIIC1 cervical cancers are candidates but must meet all the following criteria:largest node is less than 1.5 cm,less than 3 pathological nodes,No nodes located in the common iliac chain
- • Histology: squamous
- • Candidate for definitive chemoradiotherapy to be delivered with weekly cisplatin
- • Brachytherapy candidate
- • Functional State Eastern Cooperative Oncology Group (ECOG)0-2
- Exclusion Criteria:
- • Patients who had chemotherapeutic, surgical and/or radiotherapy treatment
- • FIGO stage IIIA, IIIB, IIIC2, IVA or IVB
- • FIGO stage IIIC1 with node greater than 1.5 cm, common iliac node or greater than 2 pathological nodes
- • Previous pelvic or abdominal radiotherapy
- • Patient unable to undergo MR scan
- • ECOG performance status greater than 2
- • Not a cisplatin candidate
- • Other factors that contraindicate experimental therapy
About Peking Union Medical College Hospital
Peking Union Medical College Hospital (PUMCH) is a prestigious medical institution and a leading research facility located in Beijing, China. Affiliated with the Chinese Academy of Medical Sciences, PUMCH is renowned for its commitment to advancing healthcare through innovative clinical research and high-quality patient care. The hospital plays a pivotal role in the development and execution of clinical trials across various medical disciplines, focusing on improving treatment outcomes and enhancing medical knowledge. With a multidisciplinary team of experts and state-of-the-art facilities, PUMCH is dedicated to contributing to global health advancements and fostering collaborations in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Fuquan Zhang, MD
Study Chair
Peking Union Medical College Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported